KRAS mutations correlates with P53 status in colorectal carcinomas

Natalia Rodón1, Ruth Román1, Montse Verdú1,3, Miquel Calvo4, Beatriz García-Peláez1, Marta González1, Carme Pubill3 y Xavier Puig1,2,3.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistència; 2Hospital de Barcelona-SCIAS, Grup Assistència; 3Histopat Laboratoris; 4Departament d’Estadística, Universitat de Barcelona. Barcelona

Background:

KRAS mutations, present in approximately 30-50% of colorectal carcinomas (CRC) has been recently associated with lack of response to anti-EGFR therapy, poor prognosis and high mitotic activity. Nevertheless, its relation to other histopathological and molecular parameters has not been well established.

Our first approach was to determine […]

2009-09-23T17:20:26+00:00

La pérdida de topoisomerasa II alfa está en relación con polisomia del cromosoma 17 en el carcinoma de mama con amplificación de ERBB2 (HER2)

Marta González 1, Ruth Román 1, Montse Verdú 1,3, Miriam Górriz1,3, Miquel Calvo 4, Beatriz García1, Natalia Rodón1 y Xavier Puig 1,2,3.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistència; 2Hospital de Barcelona-SCIAS, Grup Assistència; 3Histopat Laboratoris; 4Departament d’Estadística, Universitat de Barcelona. Barcelona.

 Introducción: La amplificaciones o pérdidas del gen de la topoisomerasa II alfa (TOP2A) son frecuentes en carcinomas de mama con ERBB2 amplificado. Ambas alteraciones y, recientemente, la polisomía del cromosoma 17 (cr17), se han asociado con respuesta a antraciclinas. Este […]

2009-05-23T17:40:33+00:00

Multicentric validation of a model based on phenotypic features to predict microsatellite instability in colorectal adenocarcinoma

R ROMAN1, M VERDU1,3, A VIDAL3,5, M CALVO4, X SANJUAN5, M JIMENO6, A SALAS7, J AUTONELL8, I TRIAS9, N RODON1, M GONZALEZ1, B GARCIA1 and X PUIG1,2,3.

1BIOPAT.Biopatologia Molecular, Barcelona, Spain; 2Hospital de Barcelona, Barcelona, Spain; 3Histopat Laboratoris, Barcelona, Spain; 4Statistics Department, Universitat de Barcelona, Barcelona, Spain; 5Hospital Universitari de Bellvitge, Barcelona, Spain; 6Hospital del Mar, Barcelona, Spain; 7Hospital Mútua de Terrassa, Terrasa, Spain; 8Hospital General de Vic, Vic, Spain and 9Hospital Plató, Barcelona, Spain.

Background: High microsatellite instability (MSI-H) allows the […]

2009-03-23T17:17:26+00:00

Colo-rectal micropapillary carcinoma: a clinicopathological and molecular study of 27 cases

Ruth Roman1, Montse Verdú 1,3, August Vidal 1,3, Miquel Calvo 4, Natalia Rodón1, Beatriz García1, Marta González1 and Xavier Puig1,2,3.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistencia; 2Hospital de Barcelona SCIAS, Grup Assistència; 3Histopat Laboratoris and 4Statistics Department, Universitat de Barcelona. Barcelona, Spain.

INTRODUCTION: Invasive micropapillary carcinoma (MC) is associated with frequent lymph node metastasis and adverse clinical outcome. It has been reported in ovary, breast, urinary bladder, ureter, lung, parotid gland and, recently, in colon. Little is known about the morphological and […]

2008-05-23T17:13:35+00:00

Topoisomerase II-Alpha gene copy number alterations in ERBB2-Positive primary breast carcinomas: A fluorescence in situ hybridization study

A Colomer1, N Erill1, M Górriz1,2, M Verdú2, R Roman1, R Ibáñez1, C Cordon-Cardo1 and X Puig1,2.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistència, Barcelona, Spain and 2 Histopat Laboratoris, Barcelona, Spain.

Background: Topoisomerase II-alpha gene (TOP2A) aberrations have been recently pointed as predictive markers of anthracycline-based adjuvant chemotherapy in breast cancer. While coamplification of ERBB2 and TOP2A seems to define a subgroup of high-risk patients likely to benefit from anthracycline treatment, the significance of a patient having TOP2A deletions in […]

2007-03-23T17:36:46+00:00